• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

老年直肠癌患者的三联疗法治疗结果。

Results of Tri-Modality Therapy for Rectal Cancer in Elderly Patients.

机构信息

Department of Radiation Oncology, University of Lübeck, Lübeck, Germany.

Private Practice of Radiation Oncology, Hannover, Germany.

出版信息

Anticancer Res. 2019 Nov;39(11):6217-6222. doi: 10.21873/anticanres.13830.

DOI:10.21873/anticanres.13830
PMID:31704850
Abstract

BACKGROUND/AIM: Elderly cancer patients are more prevalent and require special attention. This study focused on the outcome of elderly (≥65 years) rectal cancer patients treated with tri-modality therapy.

PATIENTS AND METHODS

A total of 105 patients receiving neoadjuvant radio-chemotherapy and resection for locally advanced rectal cancers were retrospectively evaluated. Nine characteristics were analyzed for loco-regional control (LRC), metastases-free survival (MFS) and overall survival (OS) including tumor location, gender, age, performance status, radiotherapy technique, primary tumor/lymph node categories, downstaging and histological grading.

RESULTS

The 5-year rates of LRC, MFS and OS were 91%, 78% and 87%, respectively. Radio-chemotherapy was not completed in 12 patients (11%) due to toxicity; 18 patients (17%) experienced grade 3 toxicities. A total of 29 patients (28%) had surgical complications. On multivariate analyses, MFS was significantly associated with downstaging (p=0.003) and OS with lower histological grade (p=0.013).

CONCLUSION

Tri-modality therapy resulted in promising outcomes and was tolerated reasonably well by elderly patients. Prognostic factors were identified that may help personalize future treatment.

摘要

背景/目的:老年癌症患者更为普遍,需要特别关注。本研究关注接受三联疗法治疗的老年(≥65 岁)直肠癌患者的结局。

患者和方法

回顾性评估了 105 名接受新辅助放化疗和局部晚期直肠癌切除术的患者。分析了 9 个特征,包括肿瘤位置、性别、年龄、体能状态、放疗技术、原发肿瘤/淋巴结分类、降期和组织学分级,以评估局部区域控制(LRC)、无转移生存(MFS)和总生存(OS)。

结果

5 年 LRC、MFS 和 OS 率分别为 91%、78%和 87%。由于毒性,有 12 名患者(11%)未能完成放化疗;18 名患者(17%)发生 3 级毒性。共有 29 名患者(28%)发生手术并发症。多因素分析显示,MFS 与降期显著相关(p=0.003),OS 与较低的组织学分级相关(p=0.013)。

结论

三联疗法为老年患者带来了有前景的结果,且耐受性良好。确定了预后因素,这可能有助于为未来的治疗提供个性化建议。

相似文献

1
Results of Tri-Modality Therapy for Rectal Cancer in Elderly Patients.老年直肠癌患者的三联疗法治疗结果。
Anticancer Res. 2019 Nov;39(11):6217-6222. doi: 10.21873/anticanres.13830.
2
Role of Neoadjuvant Radio-chemotherapy for the Treatment of High Rectal Cancer.新辅助放化疗在高位直肠癌治疗中的作用
Anticancer Res. 2018 Sep;38(9):5371-5377. doi: 10.21873/anticanres.12866.
3
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.奥沙利铂联合氟尿嘧啶为基础的术前放化疗和局部进展期直肠癌术后化疗(德国 CAO/ARO/AIO-04 研究):多中心、开放标签、随机、III 期临床试验的最终结果。
Lancet Oncol. 2015 Aug;16(8):979-89. doi: 10.1016/S1470-2045(15)00159-X. Epub 2015 Jul 15.
4
Phase II Trial of Preoperative Radiation With Concurrent Capecitabine, Oxaliplatin, and Bevacizumab Followed by Surgery and Postoperative 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX), and Bevacizumab in Patients With Locally Advanced Rectal Cancer: 5-Year Clinical Outcomes ECOG-ACRIN Cancer Research Group E3204.局部晚期直肠癌患者术前放疗联合卡培他滨、奥沙利铂和贝伐单抗,随后手术及术后使用5-氟尿嘧啶、亚叶酸钙、奥沙利铂(FOLFOX)和贝伐单抗的II期试验:5年临床结果 ECOG-ACRIN癌症研究组E3204
Oncologist. 2015 Jun;20(6):615-6. doi: 10.1634/theoncologist.2015-0106. Epub 2015 Apr 29.
5
[Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].[局部晚期高危直肠癌患者新辅助综合治疗的疗效与安全性分析]
Zhonghua Wei Chang Wai Ke Za Zhi. 2019 Apr 25;22(4):349-356. doi: 10.3760/cma.j.issn.1671-0274.2019.04.007.
6
Critical role of bevacizumab scheduling in combination with pre-surgical chemo-radiotherapy in MRI-defined high-risk locally advanced rectal cancer: Results of the BRANCH trial.贝伐单抗给药方案联合术前放化疗在MRI定义的高危局部晚期直肠癌中的关键作用:BRANCH试验结果
Oncotarget. 2015 Oct 6;6(30):30394-407. doi: 10.18632/oncotarget.4724.
7
The Role of Concomitant Radiation Boost in Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer.同步放疗增敏在局部晚期直肠癌新辅助放化疗中的作用
Anticancer Res. 2017 Jun;37(6):3201-3205. doi: 10.21873/anticanres.11681.
8
Capecitabine and Oxaliplatin Prior and Concurrent to Preoperative Pelvic Radiotherapy in Patients With Locally Advanced Rectal Cancer: Long-Term Outcome.卡培他滨和奥沙利铂术前同期盆腔放疗局部进展期直肠癌:长期疗效。
Clin Colorectal Cancer. 2017 Sep;16(3):240-245. doi: 10.1016/j.clcc.2016.07.008. Epub 2016 Jul 30.
9
Neoadjuvant Chemotherapy with Capecitabine, Oxaliplatin and Bevacizumab Followed by Concomitant Chemoradiation and Surgical Resection in Locally Advanced Rectal Cancer with High Risk of Recurrence - A Phase II Study.卡培他滨、奥沙利铂和贝伐单抗新辅助化疗后序贯同步放化疗及手术切除治疗复发高危局部晚期直肠癌——一项II期研究
Anticancer Res. 2017 May;37(5):2683-2691. doi: 10.21873/anticanres.11617.
10
Patients with pathological stage N2 rectal cancer treated with early adjuvant chemotherapy have a lower treatment failure rate.接受早期辅助化疗的病理分期为N2期的直肠癌患者治疗失败率较低。
BMC Cancer. 2017 Mar 9;17(1):182. doi: 10.1186/s12885-017-3170-3.

引用本文的文献

1
Clinical feasibility of the therapeutic strategies total neoadjuvant therapy and "watch and wait" in the treatment of rectal cancer patients with recurrence after clinical complete response.全新辅助治疗和“观察等待”治疗策略在临床完全缓解后复发的直肠癌患者治疗中的临床可行性
Front Surg. 2023 Jan 16;9:1006624. doi: 10.3389/fsurg.2022.1006624. eCollection 2022.
2
Influence of radiation treatment technique (IMRT vs. 3D-RT) on acute toxicity and prognostic factors for survival for anal cancer.放疗技术(调强放疗与三维适形放疗)对肛门癌急性毒性和生存预后因素的影响。
Sci Rep. 2022 Nov 19;12(1):19914. doi: 10.1038/s41598-022-24362-8.